ReviewWorld journal of gastroenterology2006
Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapy.
Review in World journal of gastroenterology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 56 citations in OpenAlex.
- Phase II study of sunitinib as second-line treatment for advanced gastric cancer.Investigational new drugs · 2011Trial
- Dissecting molecular heterogeneity in primary gastric cancer by IGFBP7-related analysis.Journal of translational medicine · 2026Article
- Comparison of the Efficacy of 35 Anticancer Drugs According to Genomic Profiling and Biological Characteristics of 14 Gastric Cancer Cell Lines.International journal of molecular sciences · 2026Article
- Review
- A literature review of recent advances in gastric cancer treatment: exploring the cross-talk between targeted therapies.Cancer cell international · 2025Review
- Repurposing of gastric cancer drugs against COVID-19.Computers in biology and medicine · 2021Article
- Tyrosine Kinases inToxins · 2019Review
- Immunohistochemical classification of gastric cancer based on new molecular biomarkers: a potential predictor of survival.Virchows Archiv : an international journal of pathology · 2018Article
- Targeting receptor tyrosine kinases in gastric cancer.World journal of gastroenterology · 2014Review
- Resistance to TRAIL is mediated by DARPP-32 in gastric cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2012Article
- MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells.Molecular cancer therapeutics · 2012Article
- An EGFR inhibitor enhances the efficacy of SN38, an active metabolite of irinotecan, in SN38-refractory gastric carcinoma cells.British journal of cancer · 2011Article
- DARPP-32 increases interactions between epidermal growth factor receptor and ERBB3 to promote tumor resistance to gefitinib.Gastroenterology · 2011Article
- Biweekly cetuximab and irinotecan as second-line therapy in patients with gastro-esophageal cancer previously treated with platinum.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2011Article
- Use of protein array technology to investigate receptor tyrosine kinases activated in hepatocellular carcinoma.Experimental and therapeutic medicine · 2011Article
- Article
- Connection between inflammation and carcinogenesis in gastrointestinal tract: focus on TGF-beta signaling.World journal of gastroenterology · 2010Review
- Overexpression of the receptor tyrosine kinase EphA4 in human gastric cancers.World journal of gastroenterology · 2008Article
- Epidermal growth factor receptor antibody plus recombinant human endostatin in treatment of hepatic metastases after remnant gastric cancer resection.World journal of gastroenterology · 2007Article
- The predictive value of 18F-FDG-PET early evaluation in patients with metastatic gastric adenocarcinoma treated with chemotherapy plus cetuximab.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Receptor tyrosine kinases (RTKs) such as the epidermal growth factor receptor family participate in several steps of tumor formation including proliferation and metastatic spread. Several known RTKs are upregulated in gastric cancer being prime targets of a tailored therapy. Only preliminary data exist, however, on the use of the currently clinically available drugs such as trastuzumab, cetuximab, bevacizumab, gefitinib, erlotinib, and imatinib in the setting of gastric cancer. Preclinical data suggest a potential benefit of their use, especially in combination with "conventional" cytostatic therapy. This review summarizes the current knowledge about their use in cancer therapy as well as new approaches and drugs to optimize treatment success.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.